Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type 1 diabetes; a randomized controlled trial

被引:129
作者
Hermanides, J. [1 ]
Norgaard, K. [2 ]
Bruttomesso, D. [3 ]
Mathieu, C. [4 ]
Frid, A. [5 ]
Dayan, C. M. [6 ]
Diem, P. [7 ,8 ]
Fermon, C. [9 ]
Wentholt, I. M. E. [1 ]
Hoekstra, J. B. L. [1 ]
DeVries, J. H. [1 ]
机构
[1] Acad Med Ctr, Dept Internal Med, NL-1100 DD Amsterdam, Netherlands
[2] Hvidovre Univ Hosp, Dept Endocrinol, DK-2650 Hvidovre, Denmark
[3] Univ Padua, Div Metab Dis, Dept Clin & Expt Med, Padua, Italy
[4] Catholic Univ Louvain, Dept Endocrinol, B-3000 Louvain, Belgium
[5] Malmo Univ Hosp, Div Diabet & Endocrinol, Malmo, Sweden
[6] Univ Bristol, Dept Med, Bristol, Avon, England
[7] Univ Hosp Bern, Div Endocrinol Diabet & Clin Nutr, CH-3010 Bern, Switzerland
[8] Univ Bern, Bern, Switzerland
[9] Ctr Hosp Roubaix, Ctr Educ Traitement Diabet & Malad Nutr, Roubaix, France
关键词
continuous blood glucose monitoring; continuous subcutaneous insulin infusion; randomized controlled trial; Type; 1; diabetes; SUBCUTANEOUS INSULIN INFUSION; GLYCEMIC CONTROL; HYPOGLYCEMIA; INJECTIONS;
D O I
10.1111/j.1464-5491.2011.03256.x
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Aims To investigate the efficacy of sensor-augmented pump therapy vs. multiple daily injection therapy in patients with suboptimally controlled Type 1 diabetes. Methods In this investigator-initiated multi-centre trial (the Eurythmics Trial) in eight outpatient centres in Europe, we randomized 83 patients with Type 1 diabetes (40 women) currently treated with multiple daily injections, age 18-65 years and HbA(1c) >= 8.2% (>= 66 mmol/mol) to 26 weeks of treatment with either a sensor-augmented insulin pump (n = 44) (Paradigm (R) REAL-Time) or continued with multiple daily injections (n = 39). Change in HbA(1c) between baseline and 26 weeks, sensor-derived endpoints and patient-reported outcomes were assessed. Results The trial was completed by 43/44 (98%) patients in the sensor-augmented insulin pump group and 35/39 (90%) patients in the multiple daily injections group. Mean HbA(1c) at baseline and at 26 weeks changed from 8.46% (SD 0.95) (69 mmol/mol) to 7.23% (SD 0.65) (56 mmol/mol) in the sensor-augmented insulin pump group and from 8.59% (SD 0.82) (70 mmol/mol) to 8.46% (SD 1.04) (69 mmol/mol) in the multiple daily injections group. Mean difference in change in HbA(1c) after 26 weeks was -1.21% (95% confidence interval -1.52 to -0.90, P < 0.001) in favour of the sensor-augmented insulin pump group. This was achieved without an increase in percentage of time spent in hypoglycaemia: between-group difference 0.0% (95% confidence interval) -1.6 to 1.7, P = 0.96). There were four episodes of severe hypoglycaemia in the sensor-augmented insulin pump group and one episode in the multiple daily injections group (P = 0.21). Problem Areas in Diabetes and Diabetes Treatment Satisfaction Questionnaire scores improved in the sensor-augmented insulin pump group. Conclusions Sensor augmented pump therapy effectively lowers HbA(1c) in patients with Type 1 diabetes suboptimally controlled with multiple daily injections.
引用
收藏
页码:1158 / 1167
页数:10
相关论文
共 24 条
[1]
Standards of medical care in diabetes 2008 [J].
不详 .
DIABETES CARE, 2008, 31 :S12-S54
[2]
Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes [J].
Bode, BW ;
Schwartz, S ;
Stubbs, HA ;
Block, JE .
DIABETES CARE, 2005, 28 (10) :2361-2366
[3]
Bradley C., 1994, Handbook of Psychology and Diabetes, P111
[4]
FEAR OF HYPOGLYCEMIA - QUANTIFICATION, VALIDATION, AND UTILIZATION [J].
COX, DJ ;
IRVINE, A ;
GONDERFREDERICK, L ;
NOWACEK, G ;
BUTTERFIELD, J .
DIABETES CARE, 1987, 10 (05) :617-621
[5]
Hypoglycemia in diabetes [J].
Cryer, PE ;
Davis, SN ;
Shamoon, H .
DIABETES CARE, 2003, 26 (06) :1902-1912
[6]
The Barrier of Hypoglycemia in Diabetes [J].
Cryer, Philip E. .
DIABETES, 2008, 57 (12) :3169-3176
[7]
Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring [J].
Deis, Dorothee ;
Bolinder, Jan ;
Riveline, Jean-Pierre ;
Battelino, Tadej ;
Bosi, Emanuele ;
Tubiana-Rufi, Nadia ;
Kerr, David ;
Phillip, Moshe .
DIABETES CARE, 2006, 29 (12) :2730-2732
[8]
Continuous glucose monitoring and external insulin pump: towards a subcutaneous closed loop [J].
Hanaire, H. .
DIABETES & METABOLISM, 2006, 32 (05) :534-538
[9]
Sense and nonsense in sensors [J].
Hermanides, J. ;
DeVries, J. H. .
DIABETOLOGIA, 2010, 53 (04) :593-596
[10]
Sensor-augmented insulin pump therapy: Results of the first randomized treat-to-target study [J].
Hirsch, Irl B. ;
Abelseth, Jill ;
Bode, Bruce W. ;
Fischer, Jerome S. ;
Kaufman, Francine R. ;
Mastrototaro, John ;
Parkin, Christopher G. ;
Wolpert, Howard A. ;
Buckingham, Bruce A. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2008, 10 (05) :377-383